IN2014DN06898A - - Google Patents

Info

Publication number
IN2014DN06898A
IN2014DN06898A IN6898DEN2014A IN2014DN06898A IN 2014DN06898 A IN2014DN06898 A IN 2014DN06898A IN 6898DEN2014 A IN6898DEN2014 A IN 6898DEN2014A IN 2014DN06898 A IN2014DN06898 A IN 2014DN06898A
Authority
IN
India
Prior art keywords
cancer
patient
adenovirus
recombinant
diagnose
Prior art date
Application number
Inventor
Clodagh OSHEA
Colin Powers
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Publication of IN2014DN06898A publication Critical patent/IN2014DN06898A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10331—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided herein are compositions and methods for detecting a cancer in a subject using a recombinant reporter adenovirus. In more particular recombinant adenovirus is used to diagnose a cancer in a patient and further used for screening compounds effective in treating the cancer in said patient.
IN6898DEN2014 2012-03-14 2013-03-14 IN2014DN06898A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610970P 2012-03-14 2012-03-14
PCT/US2013/031646 WO2013138650A1 (en) 2012-03-14 2013-03-14 Adenoviral tumor diagnostics

Publications (1)

Publication Number Publication Date
IN2014DN06898A true IN2014DN06898A (en) 2015-05-15

Family

ID=49161824

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6898DEN2014 IN2014DN06898A (en) 2012-03-14 2013-03-14

Country Status (8)

Country Link
US (2) US9885090B2 (en)
EP (1) EP2825889A4 (en)
JP (1) JP6329936B2 (en)
CN (2) CN107267554A (en)
AU (1) AU2013231972B2 (en)
CA (1) CA2865642C (en)
IN (1) IN2014DN06898A (en)
WO (1) WO2013138650A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
GB201418965D0 (en) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
US9880150B2 (en) 2015-01-28 2018-01-30 Thomas Jefferson University E2F reporter melanoma cells
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
KR102341644B1 (en) * 2015-08-04 2021-12-21 삼성디스플레이 주식회사 Liquid crystal display device and manufacturing method thereof
CA3000462C (en) 2015-10-05 2024-04-02 Salk Institute For Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
KR102471633B1 (en) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
JP2020513248A (en) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． Affinity cell extraction by sound
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
BR112020009889A2 (en) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acoustic transducer driver and controller
KR102080996B1 (en) * 2018-07-23 2020-02-25 주식회사 코어파마 Cancer cell specific adenovirus
JP7273987B2 (en) * 2019-10-25 2023-05-15 株式会社東芝 Methods, kits and programs for characterizing tumor cell populations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301506B6 (en) 1998-10-15 2010-03-31 Canji, Inc. Selectively replicating viral vectors and process of its preparation, pharmaceutical formulation, method of killing a cell having defective pathway, transformed cell and promoter responsive to p53 and TGF-{beta} pathways
AU5464000A (en) * 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
EP1593742A3 (en) * 1999-06-01 2006-02-01 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
WO2002079507A2 (en) * 2001-04-02 2002-10-10 Bayer Aktiengesellschaft Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructs
CN100475966C (en) * 2001-11-23 2009-04-08 上海三维生物技术有限公司 New-type adenovirus with tumor cell specific infection and transgenic expression capability
CN1720066B (en) * 2002-10-01 2012-05-23 杜克大学 Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
CN1424401A (en) * 2003-01-06 2003-06-18 李川源 Conditional duplicated adenovirus and its establishment and use
BRPI0414446A (en) * 2003-09-18 2006-11-14 Genmab As methods for screening for a therapeutic agent, for suppressing the polynucleotide sequence, for treating a non-steroidal cancer, for screening for binding of an agent specifically to a polynucleotide, and for determining whether a patient is at risk for developing or having a non-steroidal cancer, pharmaceutical composition, uses of a therapeutic agent, an antisense molecule or a cell that expresses and / or contains the antisense molecule, at least one of the immunogenic membrane proteins, fragments, derivatives or homologues thereof or from a cell containing and / or expressing at least one of the immunogenic membrane proteins or fragments, derivatives or homologues thereof and an agent or antibody, agent, and kit for identifying a patient at risk of developing or have non-steroidal cancer
CN100361710C (en) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
US7943373B2 (en) * 2004-09-29 2011-05-17 Oncolys Biopharma, Inc. Telomelysin/GFP-expressing recombinant virus
BRPI0517021A (en) 2004-10-25 2008-09-30 Novartis Ag tor polynucleotides and polypeptides, and methods of use
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
KR100723009B1 (en) * 2005-11-30 2007-05-29 한국원자력연구원 A pharmaceutical composition for treating malignant tumors containing human p31 genes
US20080242608A1 (en) * 2006-06-02 2008-10-02 Azad Bonni Methods and compositions for treating and preventing neurologic disorders
ES2422299T3 (en) 2006-11-28 2013-09-10 Nerviano Medical Sciences Srl Indocyls (4,5-dihydro) tricyclic indoles
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
US9261508B2 (en) * 2008-04-25 2016-02-16 Istituto Superiore Di Sanita Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration
BRPI0914223A2 (en) * 2008-06-19 2019-09-24 Millennium Pharm Inc thiophene or thiazole derivatives and their uses as p13k inhibitors
KR101034811B1 (en) * 2008-08-25 2011-05-16 단국대학교 산학협력단 Recombinant adenovirus comprising tissu-specific promoter and tumor-targeting trans-splicing ribozyme and uses thereof
CN102191245B (en) * 2010-03-15 2013-11-13 浙江东方基因生物制品有限公司 Method and reagent for detecting tumor cell in circulatory blood by applying tumor peculiar promoter to express reporter gene
WO2012003287A2 (en) * 2010-06-30 2012-01-05 The Johns Hopkins University Compositions and methods for detecting and quantifying circulating tumor cells ctcs
WO2012024351A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method

Also Published As

Publication number Publication date
EP2825889A1 (en) 2015-01-21
AU2013231972A1 (en) 2014-10-02
WO2013138650A1 (en) 2013-09-19
EP2825889A4 (en) 2015-10-28
CA2865642C (en) 2021-10-26
JP2015512507A (en) 2015-04-27
AU2013231972B2 (en) 2018-03-22
US20180100204A1 (en) 2018-04-12
US9885090B2 (en) 2018-02-06
CN104204805A (en) 2014-12-10
CA2865642A1 (en) 2013-09-19
CN107267554A (en) 2017-10-20
JP6329936B2 (en) 2018-05-23
CN104204805B (en) 2017-08-01
US20150005397A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
IN2014DN06898A (en)
IL275874A (en) Treatment methods using adenovirus
HK1213947A1 (en) Compositions and methods for diagnosing thyroid tumors
HUE049886T2 (en) Compositions of tumor specific neoantigens for use in treating tumours
IL237752B (en) Composition for enhancing specific immunotherapies in cancer treatment
HK1205008A1 (en) Dry haemostatic composition
HK1251796A1 (en) Methods and compositions for treating diabetes
MX366804B (en) R-spondin translocations and methods using the same.
HK1211487A1 (en) Oncolytic poliovirus for human tumors
IL238107B (en) Compositions comprising masitinib for use in treatment of cancer in patient subpopulations identified using predictor factors
EP2911746A4 (en) Proton treatment gantry system
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
HK1215391A1 (en) Treating oral lesions using placental extracellular matrix
BR112013014811A2 (en) cloth treatment composition
MX2013003599A (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies.
HK1215794A1 (en) Allogeneic autophagosome-enriched composition for the treatment of disease
EP2844272A4 (en) Methods and compositions for increasing red blood cells
HK1213495A1 (en) Methods and compositions for treating and diagnosing acute myocardial infarction
HK1222211A1 (en) Composition for dispersing biological tissue
SG11201502214PA (en) Adipose tissue cells
EP2881123A4 (en) Composition for treating cancer associated with hpv infection
LT2863931T (en) Compositions for use in treating wounds
EP2844347A4 (en) Compositions and methods for treating b-lymphoid malignancies
LT2863932T (en) Composition for use in the treatment of lymphedema
ES1073648Y (en) MIXED CRUSHER SCREEN